Alopecia Treatment Market Revenue Opportunies By Key Vendors Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline Plc.

Global Alopecia Treatment Market, by Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, and Alopecia Totalis), by Drug Type (Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, Immunosuppressants (Cyclosporine, and Others)), by Gender (Male and Female), by Route of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 7.4 Bn in 2017, and is projected to exhibit a CAGR of 5.6% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights. Frequent product launches, approval and robust pipeline of novel biopharmaceutical products is expected to drive the market growth in near future.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1847

For instance, in May 2018, Histogen, Inc., received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in near future. In 2017, Aclaris Therapeutics, Inc. completed Phase 1 clinical trial of ATI-50001, an investigational oral Janus Kinase (JAK) 1/3 inhibitor. ATI-50002 is a novel product indicated for treatment of treatment for alopecia areata, it is now in Phase 2 clinical trial and expected to get approval in near future. In March 2018, Aclaris Therapeutics, Inc. has patented its ATI-50002 from United States Patent and Trademark Office (USPTO). The presence of such robust pipeline of novel products is expected to create a lucrative environment for the growth of global alopecia treatment market in near future.

Browse 52 Market Data Tables and 49 Figures spread through 230 Pages and in-depth TOC on Alopecia Treatment Market By Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, and Alopecia Totalis), By Drug Type (Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, Immunosuppressants (Cyclosporine, and Others)), By Gender (Male and Female), By Route of Administration (Oral, Topical, and Injectable), By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

Increasing prevalence of alopecia among population is expected to propel demand for its treatment drugs, in turn fueling growth of market in near future. For instance, according to the data published by Arch Argent Pediatr in 2017, alopecia areata affects around 0.7 to 3% of population the U.S. and around 2% of the population is suffering from it in U.K. In Mexico, the reported prevalence is between 0.2 to 3.8%. According to the data published by Canadian Family Physician, in 2015, Alopecia areata is a form of autoimmune hair loss with a lifetime prevalence of around 2%.

To know the latest trends and insights prevalent in the alopecia treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847

Key Takeaways of the Alopecia Treatment Market:
• The global alopecia treatment market is expected to exhibit a CAGR of 5.6% over the forecast period (2018 – 2026), owing to frequent product launches, approval and robust pipeline of novel biopharmaceutical products
• North America held the dominant position in the global alopecia treatment market and is expected to retain its dominance over the forecast period (2018 – 2026). This is due to presence of major key players and advanced research for the development of novel treatment methods for alopecia. For instance, Concert Pharmaceuticals, Inc. and Aclaris Therapeutics, Inc. both are U.S.-based Company having novel products in pipeline indicated for the treatment of alopecia.
• Asia Pacific is expected to witness significant growth over the forecast period due to increasing prevalence of alopecia in key region such as Korea, China, and India. For instance, according to the data published by Arch Argent Pediatr in 2017, in Korea, it was estimated that Alopecia areata affects between 0.9% and 6.9% of individuals in general population
• Major players operating in the alopecia treatment market include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.